Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) common stock between December 27, 2023 and May 6, 2025, inclusive (the “Class Period”). Cytokinetics investors have until November 17, 2025 to file a lead plaintiff motion.

IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CYTOKINETICS, INCORPORATED (CYTK), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.

Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.

What Happened?

On May 1, 2025, Cytokinetics disclosed that the FDA has extended the review period for its cardiac myosin inhibitor drug, aficamten, by three months, citing additional time required to review newly submitted Risk Evaluation and Mitigation Strategy (REMS). The Company further revealed that, “following pre-NDA discussions with FDA in which safety and risk mitigation were discussed, Cytokinetics submitted the NDA for aficamten in oHCM without an accompanying REMS.”

On this news, Cytokinetics’s stock price fell $5.57, or 12.9%, to close at $37.35 per share on May 2, 2025, thereby injuring investors.

Then, on May 6, 2025, Cytokinetics admitted that it had multiple pre-NDA meetings with the FDA discussing safety monitoring and risk mitigation but chose to submit the NDA without a REMS, relying on labeling and voluntary education materials.

On this news, Cytokinetics’s stock price fell $0.93, or 2.7%, to close at $33.04 per share on May 7, 2025, thereby injuring investors further.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants had knowingly or recklessly omitted a REMS from the initial NDA submission, despite prior FDA discussions about safety and risk mitigation; (2) the subsequent REMS submission necessitated a three-month delay in the FDA’s process for potential approval; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Contact Us To Participate or Learn More:

If you purchased Cytokinetics common stock, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Law Offices of Howard G. Smith,

3070 Bristol Pike, Suite 112,

Bensalem, Pennsylvania 19020,

Telephone: (215) 638-4847

Email: howardsmith@howardsmithlaw.com,

Visit our website at: www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250918135884/en/